Biotech Antiverse has successfully identified functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity. Click to read more.
$3 million USD (c. £2.5 million GBP) investment will enable further development of assets Successful identification of 8 antibodies with therapeutic potential for human GPCRs achieved
Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, today announced the successful identification of functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity.
Antiverse joins Cardiff Innovations miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.